Get started
Author

Tomi Wei Jun

Gemcitabine and cisplatin plus nivolumab as organ-sparing treatment for muscle-invasive bladder cancer: a phase 2 trial
2023 · Matthew D. Galsky, Siamak Daneshmand, et al. · Nature Medicine · 145
PDF
Impact of anticoagulation prior to COVID-19 infection: a propensity score–matched cohort study
2020 · Douglas Tremblay, Maaike van Gerwen, et al. · Blood · 143
PDF
Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial
2023 · Jayesh Desai, Guzman Alonso, et al. · Nature Medicine · 133
PDF
Admission D-dimer levels, D-dimer trends, and outcomes in COVID-19
2020 · Leonard Naymagon, Nicole Zubizarreta, et al. · Thrombosis Research · 127
PDF
The Systemic Inflammatory Response Identifies Patients with Adverse Clinical Outcome from Immunotherapy in Hepatocellular Carcinoma
2021 · Ambreen Muhammed, Claudia Angela Maria Fulgenzi, et al. · Cancers · 83
PDF
Immunotherapy in Hepatocellular Cancer Patients with Mild to Severe Liver Dysfunction: Adjunctive Role of the ALBI Grade
2020 · David J. Pinato, Takahiro Kaneko, et al. · Cancers · 77
PDF
Cancer Care Disparities during the COVID-19 Pandemic: COVID-19 and Cancer Outcomes Study
2020 · Andrew L. Schmidt, Ziad Bakouny, et al. · Cancer Cell · 71
PDF
Early Antibiotic Exposure Is Not Detrimental to Therapeutic Effect from Immunotherapy in Hepatocellular Carcinoma
2021 · Petros Fessas, Muntaha Naeem, et al. · Liver Cancer · 65
PDF
Treatment-related toxicity and improved outcome from immunotherapy in hepatocellular cancer: Evidence from an FDA pooled analysis of landmark clinical trials with validation from routine practice
2021 · David J. Pinato, Thomas U. Marron, et al. · European Journal of Cancer · 64
Post-registration experience of nivolumab in advanced hepatocellular carcinoma: an international study
2020 · Petros Fessas, Ahmed Kaseb, et al. · Journal for ImmunoTherapy of Cancer · 60
PDF
Genomic and molecular features distinguish young adult cancer from later-onset cancer
2021 · William Lee, Zishan Wang, et al. · Cell Reports · 46
PDF
Analysis of sex-specific risk factors and clinical outcomes in COVID-19
2021 · Tomi Jun, Sharon Nirenberg, et al. · Communications Medicine · 46
PDF
HBV / HIV coinfection is associated with poorer outcomes in hospitalized patients with HBV or HIV
2016 · R. Rajbhandari, T. Jun, et al. · Journal of Viral Hepatitis · 45
Mac‐2 Binding Protein Glycosylation Isomer as a Hepatocellular Carcinoma Marker in Patients With Chronic Hepatitis B or C Infection
2019 · Tomi Jun, Yao‐Chun Hsu, et al. · Hepatology Communications · 43
PDF
A review of longitudinal clinical programs in US medical schools
2018 · Galina Gheihman, Tomi Jun, et al. · Medical Education Online · 42
PDF
Progression patterns and therapeutic sequencing following immune checkpoint inhibition for hepatocellular carcinoma: An international observational study
2022 · Thomas Talbot, Antonio D'Alessio, et al. · Liver International · 41
PDF
Convalescent Plasma for the Treatment of Severe COVID‐19 Infection in Cancer Patients
2020 · Douglas Tremblay, Carina Seah, et al. · Cancer Medicine · 41
PDF
Gene networks that compensate for crosstalk with crosstalk
2019 · Isaak E. Müller, Jacob R. Rubens, et al. · Nature Communications · 41
PDF
Diverse immune response of DNA damage repair-deficient tumors
2021 · Tao Qing, Tomi Jun, et al. · Cell Reports Medicine · 38
PDF
Impact of corticosteroid therapy on the outcomes of hepatocellular carcinoma treated with immune checkpoint inhibitor therapy
2020 · David J Pinato, Ahmed Kaseb, et al. · Journal for ImmunoTherapy of Cancer · 37
PDF
More advanced disease and worse survival in cryptogenic compared to viral hepatocellular carcinoma
2017 · Tomi W. Jun, Ming‐Lun Yeh, et al. · Liver International · 36
PDF
Serum M2BPGi level and risk of hepatocellular carcinoma after oral anti‐viral therapy in patients with chronic hepatitis B
2018 · Yao‐Chun Hsu, Tomi Jun, et al. · Alimentary Pharmacology & Therapeutics · 34
Single-Agent Divarasib in Patients With KRAS G12C –Positive Non–Small Cell Lung Cancer: Long-Term Follow-Up of a Phase I Study
2025 · Adrian G. Sacher, Wilson H. Miller, et al. · Journal of Clinical Oncology · 31
Oncology clinical trial disruption during the COVID-19 pandemic: a COVID-19 and cancer outcomes study
2022 · Z. Bakouny, C. Labaki, et al. · Annals of Oncology · 31
PDF
PROMISE: a real-world clinical-genomic database to address knowledge gaps in prostate cancer
2021 · Vadim S. Koshkin, Vaibhav G. Patel, et al. · Prostate Cancer and Prostatic Diseases · 31
PDF
Works count: 137
Citation count: 2,029
H-index: 27
I10-index: 44
Year
Topic
Type